On July 7, 2022, the formulation patent for the anticancer drug of MetiMedi Pharmaceutical Co., Ltd. was successfully registered in Mexico after passing examination by the Mexican Patent Office.

As a result, MetiMedi’s anticancer drug formulation patent has been registered in two countries: the United States (registered on March 29, 2022) and Mexico.

Currently, MetiMedi is in the process of further expanding its formulation patent in 13 countries, including those under the European Patent Convention (EPC), Taiwan, and Japan.